A success story in pharmacogenomics: genetic ID card for SJS/TEN

In January 2014, while scientists from resource-rich countries were discussing about whole-genome sequencing for millions of their people, to the delegates at the Global Leaders in Genomic Medicine Summit, a multinational coalition of genomic and policy experts from over 20 countries working to implement genomics in clinical care organized by the National Human Genome Research Institute and NIH - The Global Genomic Medicine Collaborative (2), a simple wallet pharmacogenetic plastic card from Thailand, a resource-limited setting, was first presented to those members. After the Global Genomic Medicine Collaborative meeting in 2014, National Human Genome Research Institute/NIH quickly organized a 2-day meeting in March 2015 to discuss research priorities for SJS/TEN, and how to monitor or manage ‘serious’ and ‘severe’ cutaneous adverse drug reactions more broadly. In summary, we recommended at least seven primary requirements to succeed the pharmacogenomics in clinical implementation: pharmacogenetics tools (pharmacogenetic card, precision medicine report and interpretation systems); pharmacogenetics infrastructure and facilities (pharmacogenomics laboratory, pharmacogenomics clinic and pharmacogenetic testing); pre- and post-pharmacogenetics counseling; pharmacogenetic knowledge and education for health professionals; pharmacovigilance system; EMR and training program for the pharmacist to be a pharmacogenetician. Financial and competing interests disclosure The authors would like to thank the Center for Medical Genomics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Thailand Center of Excellence for Life Sciences (TCELS), Ministry of Science and Technology; The Khoon Poom Foundation, The Project of Her Royal Highness Princess Ubonratana Rajakanya Siriwatana Bhanawadee; Pharmacogenomics for Autistic Children, Office of National Research Council of Thailand.